Jim Cramer Stock Picks (October 26th)

Jim Cramer’s Mad Money is one of the top watched TV shows on CNBC. Nearly two hundred fifty thousand people watch his show daily on TV and most of these are ordinary investors trying to understand what’s going on in the market. Jim Cramer’s stock picks on his show is the starting point for many investments made by these folks.

Jim Cramer

Here are Jim Cramer’s stock picks on Mad Money on October 26th:

Atlantic Power (AT): Cramer told a viewer that buying Atlantic Power without their planned acquisition might be worth the risk, especially with the 7.7% yield. Atlantic Power has a $1.16 billion market cap and trades at 49.6 times earnings.

Illinois Tool Works (ITW): Despite beating estimates on both earnings and revenue, Cramer advised a viewer to avoid Illinois Tool Works and buy Honeywell (HON) instead. Illinois Tool Works yields 3.15%, trades at 12 times earnings and has a $22.74 billion market cap.

Corning (GLW): The maker of high-tech glass for LCD screens along with optical fibers reported better than expected earnings. Corning lowered expectations to the point where it could be beaten. The company announced 50% dividend increase along with a stock buyback. Cramer said the stock seemed to have bottomed and is on its way back up. Corning yields 2.1% and trades at 6.5 times earnings.

Panera Bread (PNRA): This café-bakery concept rallied 17% Wednesday after delivering a spectacular quarter. Revenues rose 21% year-over-year and same-store sales were up 6% over the 3rd quarter. Panera Bread has a $4.07 billion market cap and trades at 27.4 times earnings.

Kimberly Clark (KMB): Although the stock didn’t make the quarter, Cramer gave it a buy recommendation on the timing of getting it for a lower price. Kimberly Clark is a “great yielder” that Cramer thinks is going to do fine. The paper company trades at 16.6 times earnings, yields 4% and has a $27.54 billion market cap. Bill Miller of Legg Mason Capital Management increased his position by 36% during the second quarter.

Jet Blue Airways (JBLU): Cramer advised a viewer to “fly it, but don’t buy it”. Jet Blue Airways has a $1.31 billion market cap and trades at 14.5 times earnings.

ImmunoGen (IMGN): Maker of the prized Da Vinci medical machines, Cramer gave ImmunoGen a buy recommendation on a belief that the stock will go higher. ImmunoGen has a $1.07 billion market cap.

Verizon (VZ): Cramer gave Verizon a buy recommendation based on their growing market share and strong yield. Verizon yields 5.5%, trades at 17.4 times earnings and has a $104 billion market cap. Ken Fisher of Fisher Asset Management owns over 94K shares.

SodaStream (SODA): Cramer urged viewers to realize that investors had a good win with SodaStream, but it is now too hard to navigate and time to let it go. SodaStream has a $538 million market cap and trades at 28 times earnings.

AT&T (T): Cramer’s charitable trust owns this telecom stock and it received a buy recommendation from him. AT&T yields 6%, trades at 14.5 times earnings and has a $170 billion market cap. George Soros of Soros Fund Management owns over 1.7M shares of AT&T.

Abercrombie & Fitch (ANF): The only teenage apparel stock Cramer would tepidly recommend, he thinks Abercrombie & Fitch can move higher. Abercrombie trades at 33 times earnings and has a $6.28 billion market cap.

B&G Foods (BGS): This “slow-and steady” packaged food company has been reinvigorating brands and recently reported in-line earnings and sales. B&G Foods yields 5% and raised forecasts for the year. B&G Foods is introducing new products across 3 of its brands. B&G has a $903.73 million market cap and trades at 18 times earnings.

Allergan (AGN): Allergan reported a good quarter with in-line revenues, but the stock still got hammered Cramer thinks this is because as the fastest-growing big pharmaceutical, simply meeting expectations isn’t enough. Allergan is both a medical and medical aesthetics company and is Cramer’s favorite vanity play. Allergan is behind Botox and develops the industry-leading lap-band and eyelash growth treatment. This pharmaceutical has a $25.55 billion market cap.